Health Care [ 5/12 ] | Biotechnology [ 51/74 ]
NASDAQ | Common Stock
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors.
Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors.
The company was incorporated in 2018 and is based in Boston, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 11, 26 | -0.93 Decreased by -36.76% | -0.65 Decreased by -43.08% |
| Mar 26, 26 | -0.68 Decreased by -74.36% | -0.65 Decreased by -3.98% |
| Nov 10, 25 | -0.67 Increased by +58.13% | -0.53 Decreased by -26.42% |
| Aug 12, 25 | -0.50 Decreased by -11.11% | -0.54 Increased by +7.41% |
| May 13, 25 | -0.68 | -0.40 Decreased by -70.00% |
| Mar 27, 25 | -0.39 | -0.28 Decreased by -38.05% |
| Nov 12, 24 | -1.60 | -0.50 Decreased by -220.00% |
| Aug 28, 24 | -0.45 | -0.43 Decreased by -4.65% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 0.00 Decreased by N/A% | -56.21 M Decreased by -52.56% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 25 | 0.00 Decreased by N/A% | -37.39 M Decreased by -78.39% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 25 | 0.00 Decreased by N/A% | -36.33 M Decreased by -107.83% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -27.39 M Decreased by -60.64% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -36.85 M Decreased by -194.58% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by N/A% | -20.96 M Decreased by -68.46% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -17.48 M Increased by +23.48% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -17.05 M Decreased by -104.18% | Decreased by N/A% - |